venetoclax,ibrutinib
Roche,AbbVie,Janssen
['ibru', 'leukemia']
new imbruvica (ibrutinib) data in fixed-duration combination regimen presented at eha 2022 shows deep, durable response at three years in untreated chronic lymphocytic leukemia 